TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7654109

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Diltiazem after hydrochlorothiazide failure
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Clonidine after atenolol failure
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Prazosin after captopril failure
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Diltiazem after clonidine failure
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Captopril after diltiazem failure
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Clonidine after prazosin failure
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Active treatment (combined response rate)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 2655256

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metimazole (2.5 g)
Number of subjects: 60
Study: 334611

Group type: EXPERIMENTAL
Intervention: Butacote (300 mg daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: fenclofenac (1200 mg daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Butacote
Number of subjects: 23

Group type: COMPARATOR
Intervention: Butacote and fenclofenac
Number of subjects: 23
Study: 31920107

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grape juice
Number of subjects: 0
Study: 31002638

Group type: EXPERIMENTAL
Intervention: Web-based lifestyle program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no program offered)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 0
Study: 28187159

Group type: EXPERIMENTAL
Intervention: CARE's Community Score Card (CSC) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community- and provider-developed indicators
Number of subjects: 0
Study: 25916220

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 μg twice daily for 12 weeks
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 21192244

Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine coformulated
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine copackaged
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine (both formulations)
Number of subjects: 120
Study: 21609157

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)‐based brief intervention and education program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Education program
Number of subjects: 62
Study: 19456003

Group type: EXPERIMENTAL
Intervention: AGS (inflatable antigravity suit)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Kentavr (non-inflatable compression garment)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (hypovolemic subjects)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AGS and Kentavr
Number of subjects: 19
Study: 16716877

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 11352

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 11352

Group type: EXPERIMENTAL
Intervention: Hydrocodone
Number of subjects: 11352
Study: 15662995

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole 1200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study: 11726841

Group type: EXPERIMENTAL
Intervention: Endoscopic injection therapy (epinephrine and polidocanol)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No endoscopic therapy (control group)
Number of subjects: 63
Study: 9160197

Group type: COMPARATOR
Intervention: North Europe
Number of subjects: 2201

Group type: COMPARATOR
Intervention: South Europe
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Both regions
Number of subjects: 2201
Study: 8125425

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 6797
Study: 3309199

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX) 15 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intrathecal methotrexate (MTX) 15 mg plus cytosine arabinoside (Ara-C) 50 mg/m2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Drugs administered via Ommaya reservoir
Number of subjects: 44

Group type: COMPARATOR
Intervention: Drugs administered via lumbar puncture
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy to the CNS
Number of subjects: 44

Group type: COMPARATOR
Intervention: No concurrent radiotherapy to the CNS
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 44
Study: 31545914

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (100 nmol/L, 12 h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study: 29345161

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg/kg body weight, 60 min pretrial)
Number of subjects: 26
Study: 26881934

Group type: EXPERIMENTAL
Intervention: SBP 110≤SBP<120
Number of subjects: 97013

Group type: EXPERIMENTAL
Intervention: SBP 120≤SBP<130
Number of subjects: 97013

Group type: EXPERIMENTAL
Intervention: SBP 130≤SBP<140
Number of subjects: 97013

Group type: EXPERIMENTAL
Intervention: SBP 140≤SBP<150
Number of subjects: 97013

Group type: EXPERIMENTAL
Intervention: SBP 150≤SBP<160
Number of subjects: 97013

Group type: EXPERIMENTAL
Intervention: SBP 160≤SBP<170
Number of subjects: 97013

Group type: EXPERIMENTAL
Intervention: SBP 170≤SBP<180
Number of subjects: 97013

Group type: EXPERIMENTAL
Intervention: SBP ≥180
Number of subjects: 97013
Study: 24045072

Group type: EXPERIMENTAL
Intervention: Aquacel(®) Ag dressing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acticoat™ dressing
Number of subjects: 100
Study: 22435251

Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Flexible Snake Scope camera (FSSC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both methods (DL and FSSC)
Number of subjects: 32
Study: 19878621

Group type: EXPERIMENTAL
Intervention: Couples' Illness Communication Scale (CICS)
Number of subjects: 288
Study: 18490931

Group type: EXPERIMENTAL
Intervention: Cod diet (3 x 150 g week(‐1))
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Salmon diet (3 x 150 g week(‐1))
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Fish oil (DHA/EPA capsules, no seafood)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 324
Study: 15986036

Group type: COMPARATOR
Intervention: Gemcitabine (GEM) alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) with continuous infusion 5-FU (CI 5-FU)
Number of subjects: 94
Study: 12185157

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation and levodopa combined
Number of subjects: 17

Group type: COMPARATOR
Intervention: Off condition (no treatment)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All treatments (Deep brain stimulation, Levodopa, both)
Number of subjects: 17
Study: 9988393

Group type: EXPERIMENTAL
Intervention: Seminal oxidative stress measurement in infertile reversal patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Seminal oxidative stress measurement in all reversal patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ROS‐TAC score as a predictor of fertility
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total antioxidant capacity measurement
Number of subjects: 30
Study: 7574193

Group type: EXPERIMENTAL
Intervention: Low blood pressure goal (target mean arterial pressure < or = 92 mm Hg for patients ≤ 60 years and < or = 98 mm Hg for patients ≥ 61 years)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual blood pressure goal (target mean arterial pressure < or = 107 mm Hg for patients ≤ 60 years and < or = 113 mm Hg for patients ≥ 61 years)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Low blood pressure goal
Number of subjects: 840
Study: 1689417

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 359110

Group type: EXPERIMENTAL
Intervention: Meperidine 50 mg
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Meperidine 75 to 150 mg
Number of subjects: 920

Group type: COMPARATOR
Intervention: No Meperidine (Control)
Number of subjects: 920
Study: 30907180

Group type: EXPERIMENTAL
Intervention: Psychological counselling (PC) and Nutritional Counselling (NC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nutritional treatment (Control Group)
Number of subjects: 40
Study: 31161927

Group type: EXPERIMENTAL
Intervention: Shilajit supplementation (125 or 250 mg bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shilajit supplementation (250 mg bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shilajit supplementation
Number of subjects: 0
Study: 28550195

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26081815

Group type: EXPERIMENTAL
Intervention: Cediranib (an inhibitor of vascular endothelial growth factor receptors) combined with carboplatin-paclitaxel
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 23564425

Group type: EXPERIMENTAL
Intervention: Plantar incision
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dorsal incision
Number of subjects: 76
Study: 21650085

Group type: EXPERIMENTAL
Intervention: LFM-A13
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: LFM-A13 + Vincristine
Number of subjects: 135
Study: 18777156

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 5
Study: 16132055

Group type: EXPERIMENTAL
Intervention: 8 g per day of water-soluble fiber from oat bran
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 14735366

Group type: EXPERIMENTAL
Intervention: Computer-assisted infrared thermography
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CRPS1 patients
Number of subjects: 18
Study: 11762655

Group type: EXPERIMENTAL
Intervention: Anticonvulsant medication
Number of subjects: 111

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 111
Study: 10960380

Group type: EXPERIMENTAL
Intervention: 4 mL of 1.5% (60‐mg dose) plain mepivacaine (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 mL of 2% (80‐mg dose) plain mepivacaine (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both doses of plain mepivacaine
Number of subjects: 60
Study: 8985797

Group type: EXPERIMENTAL
Intervention: Home-Care Rehabilitation Program (HCRP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 1289359

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 234

Group type: COMPARATOR
Intervention: Piperacillin plus gentamicin
Number of subjects: 234
Study: 6367533

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 10 mg domperidone
Number of subjects: 77

Group type: COMPARATOR
Intervention: NaCl as placebo
Number of subjects: 77
Study: 29290182

Group type: EXPERIMENTAL
Intervention: Continuous Epidural Analgesia (Group E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-Shot Femoral Nerve Block (Group F)
Number of subjects: 60
Study: 27143676

Group type: EXPERIMENTAL
Intervention: Computed tomography angiography testing
Number of subjects: 10003

Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 10003
Study: 25113139

Group type: EXPERIMENTAL
Intervention: Motivational counseling intervention (4 individual sessions)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control (usual lifestyle)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Motivational counseling intervention
Number of subjects: 166
Study: 21878804

Group type: EXPERIMENTAL
Intervention: 3-week nutritional supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20083428

Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic field (EMF) emitted by a mobile phone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 10
Study: 17434095

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH), nadroparin calcium 3800 anti-factor Xa IU/0.4 mL twice daily for 10 days, then aspirin 80-300 mg once daily for 6 months
Number of subjects: 353

Group type: COMPARATOR
Intervention: Aspirin 160 mg daily for 10 days, then aspirin 80-300 mg once daily for 6 months
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 353
Study: 15685040

Group type: COMPARATOR
Intervention: Chemotherapy with DDP (80 mg/m2 intravenously day 1 only) and VP-16 (80 mg/m2 intravenously days 1-3) every 3 weeks for 5 cycles without tamoxifen.
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Chemotherapy with DDP and VP-16 plus high-dose tamoxifen (80 mg orally twice per day for 5 days each cycle starting 1 day before DDP).
Number of subjects: 319
Study: 11854640

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (200 microg initially, increased to 300 microg)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Intravaginal misoprostol (50 microg initially, increased to 100 microg)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol
Number of subjects: 157

Group type: COMPARATOR
Intervention: Intravaginal misoprostol
Number of subjects: 157
Study: 10463751

Group type: EXPERIMENTAL
Intervention: human recombinant osteogenic protein (OP-1) on a collagen type-I carrier
Number of subjects: 24

Group type: COMPARATOR
Intervention: collagen type-I alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: demineralised bone
Number of subjects: 24

Group type: COMPARATOR
Intervention: untreated group
Number of subjects: 24
Study: 7541064

Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine combination therapy for 2 years
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transient HIV suppression
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Zidovudine resistance
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Multidrug resistance
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mutations in > or = 4 patients each
Number of subjects: 35
Study: 2355814

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 500 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Inert placebo (Pla)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) during acute hypoxia
Number of subjects: 27

Group type: COMPARATOR
Intervention: Inert placebo (Pla) during acute hypoxia
Number of subjects: 27
Study: 30590606

Group type: EXPERIMENTAL
Intervention: Post-operative therapy with capecitabine and oxaliplatin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 150
Study: 29901635

Group type: EXPERIMENTAL
Intervention: Rapamycin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 25394608

Group type: EXPERIMENTAL
Intervention: Group lifestyle intervention (educational intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (routine prenatal care)
Number of subjects: 60
Study: 24793669

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (one 5‐minute inflation of a blood pressure cuff to 200 mm Hg around the upper arm)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (no remote ischemic preconditioning)
Number of subjects: 94
Study: 23131285

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation + Continuous blood purification (CBP) with bicarbonate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation + Continuous blood purification (CBP) with lactate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mechanical ventilation (control group)
Number of subjects: 26
Study: 20500533

Group type: EXPERIMENTAL
Intervention: High adherence to drug (> 80% of days covered)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low adherence to drug (< 50% of days covered)
Number of subjects: 0
Study: 18559019

Group type: EXPERIMENTAL
Intervention: Exercise and Breast Cancer: A Booklet for Breast-Care Nurses
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 92
Study: 15821182

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untrained group (control)
Number of subjects: 30
Study: 12365468

Group type: EXPERIMENTAL
Intervention: Discontinuation of metformin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Insulin only (Control)
Number of subjects: 90
Study: 10585981

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of Adderall received in the morning only
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of MPH received twice (7:30 AM and 11:30 AM) with 0.15 mg/kg received at 3:30 PM
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of MPH at 3:30 PM
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Adderall in the morning and placebo at 3:30 PM
Number of subjects: 21
Study: 8721804

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 7788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7788
Study: 1846848

Group type: EXPERIMENTAL
Intervention: Cisplatin 3.2 mg/m2/24 hr with 66 Gy in 33 fractions over 6 1/2 weeks for NSCLC
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cisplatin 4.0 mg/m2/24 hr with 45 Gy in 25 fractions over 5 weeks for rectal carcinoma
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cisplatin 5.0 mg/m2/24 hr
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intraoperative electron boost
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Further external beam therapy up to 59.4 Gy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: No further therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Toxicity related to cisplatin dose
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose
Number of subjects: 31
Study: 6194934

Group type: EXPERIMENTAL
Intervention: 5% albumin (A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 6% hetastarch (H)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.9% saline (S)
Number of subjects: 26
Study: 31492016

Group type: EXPERIMENTAL
Intervention: 1-month breast milk sCD14 levels in the atopic dermatitis (AD) group
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 1-month breast milk sCD14 levels
Number of subjects: 258
Study: 29273077

Group type: EXPERIMENTAL
Intervention: Face-to-face training intervention for frontline officers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine training
Number of subjects: 0
Study: 27040515

Group type: EXPERIMENTAL
Intervention: BNP tertile 1 (BNP ≤ 376 pg/mL)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: BNP tertile 2 (BNP 377 to 792 pg/mL)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: BNP tertile 3 (BNP ≥ 793 pg/mL)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Hemodynamic markers measured via pulmonary artery catheter
Number of subjects: 251
Study: 24339313

Group type: EXPERIMENTAL
Intervention: Oral hygienic care program (OHCP) including tooth brushing with an inter-dental brush and tongue cleaner, and cleaning with chlorhexidine, administered once per day for a mean duration of 2.2 weeks.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no OHCP).
Number of subjects: 56
Study: 21288666

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg DM Se
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 2 mg/kg DM Se
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 4 mg/kg DM Se
Number of subjects: 119

Group type: COMPARATOR
Intervention: 0 mg/kg DM Se (Control)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Se-deficient (Group 1)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Se-excess (Group 4)
Number of subjects: 119
Study: 19730959

Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 31

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 31
Study: 17503747

Group type: EXPERIMENTAL
Intervention: Induction/maintenance (IM) therapy: two NRTIs + one NNRTI + one protease inhibitor for 24-32 weeks, followed by two NRTIs + NNRTI
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard therapy (ST): two NRTIs + NNRTI
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Induction/maintenance (IM) therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 122
Study: 15201565

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, flexible)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 11584456

Group type: EXPERIMENTAL
Intervention: Active abdominal generator position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Active pectoral generator position
Number of subjects: 25
Study: 9554347

Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil (500 microg)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Prazosin (2,000 microg)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Alprostadil-prazosin combination (500/2,000 microg)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Alprostadil (125 microg)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Alprostadil (250 microg)
Number of subjects: 234